Caricamento...

Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab

BACKGROUND: Management of disease-modifying therapies in Multiple Sclerosis (MS) during the COVID-19 pandemic is a controversial issue. Alemtuzumab is an immunosuppressive drug that induces lymphocytes depletion. In this study, we aimed to evaluate the frequency and severity of COVID-19 in a case se...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mult Scler Relat Disord
Autori principali: Matías-Guiu, Jorge, Montero-Escribano, Paloma, Pytel, Vanesa, Porta-Etessam, Jesús, Matias-Guiu, Jordi A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier B.V. 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286822/
https://ncbi.nlm.nih.gov/pubmed/32554284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102297
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !